An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method

Trial Profile

An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Acute lymphoblastic leukaemia; Leukaemia; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Oct 2017 Results from this and 2 otehr studies, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 24 Jan 2017 Status changed from recruiting to completed.
    • 06 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top